Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 66% Improvement Relative Risk ICU admission 17% Hospital stay >8 days 21% c19early.org/d Gönen et al. Vitamin D for COVID-19 Sufficiency Favors vitamin D Favors control
Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1
Gönen et al., Nutrients, doi:10.3390/nu13114047
Gönen et al., Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2).., Nutrients, doi:10.3390/nu13114047
Nov 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 867 hospitalized COVID-19 patients in Turkey, showing worse outcomes with vitamin D deficiency (without statistical significance); followed by a prospective study of 210 patients with vitamin D supplementation for those that were deficient, showing significantly lower mortality compared to the retrospective study without treatment.
risk of death, 65.8% lower, RR 0.34, p = 0.62, high D levels (≥12ng/mL) 1 of 80 (1.2%), low D levels (<12ng/mL) 3 of 82 (3.7%), NNT 42, retrospective study.
risk of ICU admission, 16.9% lower, RR 0.83, p = 1.00, high D levels (≥12ng/mL) 4 of 77 (5.2%), low D levels (<12ng/mL) 5 of 80 (6.2%), NNT 95, retrospective study.
hospital stay >8 days, 21.1% lower, RR 0.79, p = 0.11, high D levels (≥12ng/mL) 40 of 78 (51.3%), low D levels (<12ng/mL) 52 of 80 (65.0%), NNT 7.3, retrospective study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gönen et al., 12 Nov 2021, retrospective, Turkey, peer-reviewed, 20 authors, dosage varies.
Contact: karraspiros@yahoo.gr, duygugezenak@iuc.edu.tr, duygugezenak@gmail.com, erdinc.dursun@iuc.edu.tr, erdincdu@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: nutrients Article Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1 Mustafa Sait Gönen 1 , Merve Alaylıoğlu 2 , Emre Durcan 1 , Yusuf Özdemir 3 , Serdar Şahin 1 , Dildar Konukoğlu 4 , Okan Kadir Nohut 5 , Seval Ürkmez 6 , Berna Küçükece 7 , İlker İnanç Balkan 3 , H. Volkan Kara 8 , Şermin Börekçi 9 , Hande Özkaya 1 , Zekayi Kutlubay 10 , Yalım Dikmen 6 , Yılmaz Keskindemirci 11,12 , Spyridon N. Karras 13, * , Cedric Annweiler 14,15 , Duygu Gezen-Ak 2, * and Erdinç Dursun 2,16, * 1 2   3 Citation: Gönen, M.S.; Alaylıoğlu, M.; Durcan, E.; Özdemir, Y.; Şahin, S.; 4 Konukoğlu, D.; Nohut, O.K.; Ürkmez, S.; Küçükece, B.; Balkan, İ.İ.; et al. 5 Rapid and Effective Vitamin D Supplementation May Present Better 6 Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1. 7 8 Nutrients 2021, 13, 4047. https:// doi.org/10.3390/nu13114047 9 Academic Editors: Maria 10 Luz Fernandez, Andrea Fabbri and Sara Gandini Received: 15 September 2021 Accepted: 11 November 2021 Published: 12 November 2021 Publisher’s Note: MDPI stays neutral 11 12 13 14 15 with regard to jurisdictional claims in published maps and institutional affil- 16 iations. * Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Endocrinology and Metabolism Unit, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; sait.gonen@iuc.edu.tr (M.S.G.); dr.durcan@hotmail.com (E.D.); srdr_shn@hotmail.com (S.Ş.); hmba@iuc.edu.tr (H.Ö.) Brain and Neurodegenerative Disorders Research Laboratories, Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; merve.alaylioglu@hotmail.com Department of Infectious Diseases and Clinical Microbiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; ozdemiryusufemre1990@gmail.com (Y.Ö.); ilkerinancbalkan@hotmail.com (İ.İ.B.) Department of Medical Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; dkonuk@istanbul.edu.tr Fikert Biyal Biochemistry Laboratory, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; okannohut@hotmail.com Department of Anesthesiology and Reanimation, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; seval.urkmez@istanbul.edu.tr (S.Ü.); ydikmen@iuc.edu.tr (Y.D.) Cerrahpasa Hospital Pharmacy Unit, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; bernakucukece11@gmail.com Department of Thoracic Surgery, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; volkan_kara@yahoo.com Department of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; borekcisermin@gmail.com Dermatology and Venerology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey; zekayikutlubay@hotmail.com General Directorate of Hospitals, Istanbul University-Cerrahpasa, Istanbul..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit